Key result
Amlodipine showed no difference in mortality or major cardiovascular events compared to other antihypertensives in high-risk patients, but decreased stroke risk across groups and increased CHF risk in diabetic patients.
Why the study?
Does amlodipine reduce cardiovascular events and blood pressure in hypertensive patients with diabetes and/or renal dysfunction compared to other antihypertensive medications?
Meta-Analysis
Does amlodipine reduce cardiovascular events and blood pressure in hypertensive patients with diabetes and/or renal dysfunction compared to other antihypertensive medications?
Amlodipine is an effective antihypertensive option that reduces stroke risk in high-risk patients with diabetes or renal dysfunction, though it may increase the risk of heart failure in diabetic patients.
Answers are grounded in this paper and cite their sources.
Supports amlodipine for stroke prevention in high-risk hypertension; extends Level 1 evidence on CHF risk in diabetes.
The long-term cardiovascular (CV) effects of calcium channel blockers, with special focus on amlodipine, were compared with other classes of antihypertensive medications in high-risk hypertensive patient subgroups. A systematic literature review and meta-analysis was undertaken of 38 unique randomized, active-controlled, parallel-group trials comparing amlodipine/calcium channel blockers with diuretics, β-blockers, α-blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers, with ≥6-month follow-up, and which had included assessment of blood pressure (BP) and CV events [all-cause death, CV death, myocardial infarction (MI), stroke, congestive heart failure (CHF), or major CV events (MACE: MI, CHF, stroke, and CV death)], in hypertensive patients (baseline systolic/diastolic BP ≥140/≥90 mm Hg) with either concomitant diabetes and/or renal dysfunction. In hypertensive patients with diabetes, no difference was found for amlodipine versus comparators with respect to all-cause death, CV death, MACE, and MI; a decrease in stroke risk, and an increase in CHF risk, was seen. In hypertensive patients with renal dysfunction, no difference was found for amlodipine versus comparators with respect to all-cause death, CV death, MACE, MI, and CHF; a decrease in stroke risk was seen. Amlodipine was found to be at least as efficacious as all the other classes of antihypertensive agents in reducing systolic and diastolic BP. Long-term control of BP is critical for avoiding complications of hypertension in high-risk patients, particularly CV and cerebrovascular events such as stroke. This analysis has provided evidence that amlodipine is an appealing therapeutic option in the long-term management of hypertension in both diabetic and renal dysfunction patients.
No takes yet. Share an insight, caveat, or question.
Jeffers et al. (2015) conducted a meta-analysis in Hypertension with concomitant diabetes mellitus and/or renal dysfunction. Amlodipine vs. Diuretics, β-blockers, α-blockers, ACE inhibitors, or ARBs was evaluated on Blood pressure and cardiovascular events (all-cause death, CV death, MI, stroke, CHF, or MACE). Amlodipine showed no difference in mortality or major cardiovascular events compared to other antihypertensives in high-risk patients, but decreased stroke risk across groups and increased CHF risk in diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: